Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97,755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers.
Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, Kim TS, Choi SJ, Kim HD, Han JW, Kwon M, Kim JH, Lee AJ, Nam SK, Bae SJ, Lee SB, Shin SJ, Park SH, Ahn JB, Jung I, Lee KY, Park SH, Kim H, Min BS, Shin EC. Kim CG, et al. Among authors: kim ts, kim h, kim y, kim hd, kim kh, kim jh. Sci Immunol. 2019 Nov 8;4(41):eaay0555. doi: 10.1126/sciimmunol.aay0555. Sci Immunol. 2019. PMID: 31704735
TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.
Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Seo SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC. Han HS, et al. Among authors: kim h, kim ar, kim hk, kim wj, kim hd, kim wt. Cancer Lett. 2021 Feb 28;499:137-147. doi: 10.1016/j.canlet.2020.11.035. Epub 2020 Nov 27. Cancer Lett. 2021. PMID: 33249194
Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer.
Kim BS, Kuen DS, Koh CH, Kim HD, Chang SH, Kim S, Jeon YK, Park YJ, Choi G, Kim J, Kang KW, Kim HY, Kang SJ, Hwang S, Shin EC, Kang CY, Dong C, Chung Y. Kim BS, et al. J Immunother Cancer. 2021 Jun;9(6):e002603. doi: 10.1136/jitc-2021-002603. J Immunother Cancer. 2021. PMID: 34083422 Free PMC article.
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
Jeong S, Park E, Kim HD, Sung E, Kim H, Jeon J, Kim Y, Jung UJ, Son YG, Hong Y, Lee H, Lee S, Lim Y, Won J, Jeon M, Hwang S, Fang L, Jiang W, Wang Z, Shin EC, Park SH, Jung J. Jeong S, et al. Among authors: kim h, kim hd, kim y. J Immunother Cancer. 2021 Jul;9(7):e002428. doi: 10.1136/jitc-2021-002428. J Immunother Cancer. 2021. PMID: 34230109 Free PMC article.
97,755 results
You have reached the last available page of results. Please see the User Guide for more information.